Mallinckrodt acquires device for delivering immunotherapy for $1.3B

Mallinckrodt ($MNK) continued its wheeling and dealing with the planned $1.3 billion acquisition of Therakos, maker of a drug/device combination product that delivers immunotherapies to hospitalized patients. The move comes on the heels of the announcement of the sale of Mallinckrodt's contrast media and delivery systems business to Paris-based Guerbet for about $270 million. "Therakos is, quite simply, another excellent fit for Mallinckrodt. It is an immunotherapy treatment for patients who may have exhausted other therapies, with significant potential value in a variety of complex disease states and conditions. Installed in more than 350 academic medical centers and hospitals around the world, it is delivered in hospital-based out-patient clinics via an innovative, fully integrated, drug-device combination that is widely reimbursed globally," said Mallinckrodt CEO Mark Trudeau. More